Drug Profile


Alternative Names: BHV-4157; FC 4157

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company
  • Class Benzothiazoles; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obsessive-compulsive disorders
  • Discontinued Spinocerebellar degeneration

Most Recent Events

  • 02 Oct 2017 Discontinued - Phase-II/III for Spinocerebellar degeneration in USA following negative topline results (PO)
  • 02 Oct 2017 Topline efficacy data from a phase II/III trial in Spinocerebellar degeneration released by Biohaven Pharmaceutical Holding Company
  • 28 Sep 2017 US FDA approves IND application for Trigriluzole in Obsessive-compulsive disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top